IO Biotech Inc

NASDAQ IOBT

Data sourced from

and

Download Data

IO Biotech Inc Selling, General, and Administrative Expenses (SG&A) 3 year CAGR for the year ending December 31, 2023: 141.29%

IO Biotech Inc Selling, General, and Administrative Expenses (SG&A) 3 year CAGR is 141.29% for the year ending December 31, 2023, a 7.64% change year over year. Selling, General, and Administrative Expenses (SG&A) consit of the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

IO Biotech Inc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2022 was USD 24.44 M, a 120.52% change year over year.
IO Biotech Inc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2021 was USD 11.08 M, a 559.25% change year over year.
IO Biotech Inc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2020 was USD 1.68 M, a -14.93% change year over year.
IO Biotech Inc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2019 was USD 1.98 M.

NASDAQ: IOBT

IO Biotech Inc

CEO	Dr. Mai-Britt Zocca Ph.D.
IPO Date	Nov. 5, 2021
Location	Denmark
Headquarters	Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
Employees	68
Sector	Healthcare
Industry	Biotechnology

Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Key trends